Surgery Partners, Inc. (NASDAQ:SGRY) Receives $37.38 Average Target Price from Analysts

Surgery Partners, Inc. (NASDAQ:SGRY) has earned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $36.56.

SGRY has been the topic of a number of research reports. Benchmark reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Surgery Partners in a report on Monday, August 26th. UBS Group began coverage on shares of Surgery Partners in a research note on Monday, October 14th. They issued a “buy” rating and a $38.00 price target on the stock. Bank of America started coverage on shares of Surgery Partners in a research report on Monday. They set a “buy” rating and a $30.00 price target on the stock. Royal Bank of Canada cut their price objective on shares of Surgery Partners from $49.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, November 20th. Finally, KeyCorp began coverage on shares of Surgery Partners in a report on Friday, October 11th. They set a “sector weight” rating on the stock.

Surgery Partners Stock Performance

NASDAQ SGRY opened at $21.60 on Friday. The stock has a market cap of $2.75 billion, a PE ratio of -45.00, a P/E/G ratio of 17.40 and a beta of 2.58. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.66 and a current ratio of 1.80. The firm has a 50-day moving average of $26.93 and a 200-day moving average of $27.98. Surgery Partners has a 52-week low of $19.90 and a 52-week high of $35.29.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.06). Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. The company had revenue of $770.40 million during the quarter, compared to the consensus estimate of $768.99 million. During the same period in the prior year, the company earned $0.15 earnings per share. The firm’s revenue was up 14.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Surgery Partners will post 0.71 EPS for the current year.

Institutional Trading of Surgery Partners

Several large investors have recently made changes to their positions in SGRY. Quarry LP raised its position in Surgery Partners by 133.1% during the second quarter. Quarry LP now owns 3,082 shares of the company’s stock valued at $73,000 after purchasing an additional 1,760 shares in the last quarter. KBC Group NV boosted its holdings in shares of Surgery Partners by 31.8% in the 3rd quarter. KBC Group NV now owns 2,385 shares of the company’s stock valued at $77,000 after purchasing an additional 576 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Surgery Partners by 747.6% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,831 shares of the company’s stock valued at $124,000 after purchasing an additional 3,379 shares during the last quarter. Creative Planning acquired a new position in shares of Surgery Partners during the 3rd quarter worth $258,000. Finally, Versor Investments LP bought a new stake in shares of Surgery Partners during the 3rd quarter worth $271,000.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.